ELVN — Enliven Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1672619 ·
Last close
$46.85
Market Cap
$3.45B
52W High
$62.32
52W Low
$14.78
ADV30
1,438,709
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -36,045,000 | -27,703,000 | 897,225,000 | 151,667,000 | 20,278,000 |
| Jun 2026 | 0 | — | -37,209,000 | -32,485,000 | 910,223,000 | 135,505,000 | 15,074,000 |
| Mar 2026 | 0 | — | -27,823,000 | -23,627,000 | 464,852,000 | 132,184,000 | 11,487,000 |
| Dec 2025 | 0 | — | -34,285,000 | -29,667,000 | 476,168,000 | 98,896,000 | 16,568,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-66,939,000
Investing CF
$-390,719,000
Financing CF
$473,726,000
CapEx
$-159,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.67
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-403,278,000
Inventory
—
Receivables
—
ST Investments
$759,650,000
EBIT TTM
$-124,413,000
Pretax Income TTM
$-105,927,000
Interest Exp TTM
—
Analysts
12
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -119,658,000 | -103,694,000 | 476,168,000 | 16,568,000 | 459,600,000 | -70,301,000 |
| Dec 2024 | 0 | -104,554,000 | -89,024,000 | 325,760,000 | 15,915,000 | 309,845,000 | -73,192,000 |
| Dec 2023 | 0 | -83,529,000 | -71,584,000 | 271,867,000 | 25,961,000 | 245,906,000 | -61,269,000 |
| Dec 2022 | 0 | -38,791,000 | -37,662,000 | 83,298,000 | 160,123,000 | -76,825,000 | -32,077,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-105,927,000
OpCashFlow TTM
—
Assets (Latest)
$910,223,000
Forward EPS
$-2.14
Max Pain — expiry 2027-03-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $25.00 · spot: $44.89 · call volume: 194 · put volume: 60Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARQT | Arcutis Biotherapeutics, Inc. | $3.46B | $27.33 | — |
| VKTX | Viking Therapeutics, Inc. | $3.43B | $26.88 | — |
| VRDN | Viridian Therapeutics, Inc.\DE | $3.41B | $30.06 | — |
| IRON | Disc Medicine, Inc. | $3.49B | $76.57 | — |
| PBLS | Parabilis Medicines, Inc. | $3.49B | $28.25 | — |
News headlines (Yahoo Finance, 1h cache)
Enliven Therapeutics Stock In Focus After Wider Loss And FDA Trial Alignment
2026-11-07 16:13 · Yahoo
Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update
2026-11-05 21:05 · Yahoo
Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year
2026-10-14 20:30 · Yahoo
Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial
2026-10-07 15:21 · Yahoo
Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia
2026-10-06 20:05 · Yahoo
Enliven Therapeutics to Present at Upcoming Investor Conferences
2026-09-03 20:05 · Yahoo
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
2026-08-31 22:05 · Yahoo
Enliven Therapeutics (ELVN) Stock Looks Overvalued As Returns Surge But Book Value Lags
2026-07-04 06:10 · Yahoo
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally
2026-06-27 16:23 · Yahoo
What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%
2026-06-27 19:56 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.